What is the New Adderall?

If you are wondering if there are new versions of Adderall, look no further! There are several new drugs available on the market. Here are four of them: Cognizin, Adzenys, and XR-ODT. Let’s look at each one of them in detail and see if any of them have the same effect. Ultimately, you’ll have to decide for yourself which one is best for your child.

Adzenys

Adzenys is an extended-release oral tablet, or ODT, that is taken once daily. The drug is safe and easy to take. It comes in a child-proof package and tastes like orange candy. It is intended to treat inattentiveness, impulsive behavior, and hyperactivity in both adults and children. It is a Schedule II controlled substance that may be addictive. Before taking Adzenys, talk with your doctor to determine whether it is right for you.

The extended-release form of Adzenys is similar to other ADHD-treatment stimulants. It is habit-forming and contains dextroamphetamine, which makes it a Schedule II controlled substance. The medication works quickly, starting working within an hour of administration. The tablet has a half-life of about 12 hours. It is recommended to take the tablet in the morning, as it can make sleep difficult.

Sunosi

Although clinical trials for Sunosi are not yet complete, they did find no significant changes in blood pressure or heart rate. The clinical trials involved people with narcolepsy and obstructive sleep apnea (OSA). Blood pressure measurements include the first number, Systolic, and the second number, Diastolic, which measures the pressure inside the blood vessels when the heart relaxes. In addition to these findings, the clinical trials involved different strengths of Sunosi.

Sunosi is a prescription medication and has a number of side effects. Some of these may be serious, such as high blood pressure. It may also cause a fast heart rate, so use with caution. People with end-stage kidney disease should not take Sunosi if they already have heart disease or are taking other drugs that increase blood pressure. The drug is also not recommended for use in children under the age of 12.

Adzenys XR-ODT

The latest version of Adderall is now available as an extended-release orally disintegrating tablet. It is taken once daily and disintegrates in your mouth. The tablets are suitable for children aged six and older. Adzenys XR-ODT is a Schedule II controlled substance. If taken improperly, the drug may cause addiction, so proper storage is a must.

Adzenys XR-ODD is safe for children and adults but may have serious side effects. Side effects include slowed growth in children, heart-related problems, increased blood pressure and heart rate, and even sudden death. It may also cause a person to experience aggressiveness, psychosis, or suicidal ideation. If you are pregnant, you should consult a doctor before taking this drug.

While Adzenys XR-ODD is generally safe, it does interact with a number of drugs. For example, it may interact with MAO inhibitors and lithium. Other drugs it may interact with include antidepressants, narcotic pain medications, seizure medications, and blood thinners. Also, Adzenys XR-ODT has been linked to cardiovascular problems and can cause fainting.

Cognizin

A better alternative to Adderall, Cognizin is a proprietary blend that contains no stimulants and enhances brain function by promoting neural regeneration. It also prevents memory loss and neurodegenerative disorders. Phosphatidylserine is a plant derived amino acid that is excellent for cognitive performance. It aids in improving focusing abilities, memory, and response time. There are many positive reviews about Cognizin, and a number of top-rated reviews on this new addition to the Adderall family.

Cognizin contains vitamins, minerals, and herbal extracts that have been proven to boost brain functions and improve mental energy. The supplement is designed to provide more time throughout the day with no side effects. It enhances the human brain to achieve top-level thinking capabilities. But, should it be the new Adderall? Let’s find out. Let’s see how this new product stacks up to the old drug.

Benjamin Guffoggio